U.S. Pharmaceuticals & Biotech Most Popular Stocks

Nika Pharmaceuticals

Market Cap: US$301.7m

A pharmaceutical company, develops drugs for the treatment of HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes, and various other diseases.

Aldeyra Therapeutics

Market Cap: US$300.8m

A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.

Candel Therapeutics

Market Cap: US$298.1m

A clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients.

Neumora Therapeutics

Market Cap: US$296.4m

A clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.

Contineum Therapeutics

Market Cap: US$294.4m

A clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States.

Vanda Pharmaceuticals

Market Cap: US$289.5m

A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

Mereo BioPharma Group

Market Cap: US$286.4m

A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.

Omeros

Market Cap: US$285.8m

A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.

Abeona Therapeutics

Market Cap: US$284.6m

A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.

Capricor Therapeutics

Market Cap: US$283.0m

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Tectonic Therapeutic

Market Cap: US$280.5m

A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs).

Kyverna Therapeutics

Market Cap: US$278.5m

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.

Foghorn Therapeutics

Market Cap: US$277.6m

A clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.

Allogene Therapeutics

Market Cap: US$272.9m

A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

AC Immune

Market Cap: US$270.1m

A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

Forte Biosciences

Market Cap: US$267.5m

Operates as a clinical-stage biopharmaceutical company in the United States.

Humacyte

Market Cap: US$266.8m

Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

Jade Biosciences

Market Cap: US$264.9m

Operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.

Lifecore Biomedical

Market Cap: US$264.1m

Operates as an integrated contract development and manufacturing organization in the United States.

Aardvark Therapeutics

Market Cap: US$264.1m

A clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.

Cartesian Therapeutics

Market Cap: US$261.8m

A clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.

Tenax Therapeutics

Market Cap: US$259.9m

A clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.

Lyell Immunopharma

Market Cap: US$258.4m

A clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.

Tenaya Therapeutics

Market Cap: US$254.2m

A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

Crescent Biopharma

Market Cap: US$253.8m

A biotechnology company, researches and develops cancer therapy candidates.

Quanterix

Market Cap: US$246.3m

A life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.

Neurogene

Market Cap: US$246.2m

A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.

Atlantic International

Market Cap: US$245.2m

Operates as a staffing company servicing the commercial, professional, finance, direct placement, and managed service provider verticals.

Silence Therapeutics

Market Cap: US$242.8m

A biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

Perspective Therapeutics

Market Cap: US$242.1m

Develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.

TriSalus Life Sciences

Market Cap: US$241.4m

Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers.

Invivyd

Market Cap: US$237.8m

A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

Puma Biotechnology

Market Cap: US$237.7m

A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.

Vor Biopharma

Market Cap: US$237.3m

Operates as a clinical-stage cell and genome engineering company.

Exagen

Market Cap: US$237.2m

Designs, develops, and commercializes various testing products under the AVISE brand in the United States.

Sagimet Biosciences

Market Cap: US$236.8m

A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.